This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jonathan O. Cole, MD
From the Psychopharmacology Program, McLean Hospital, Belmont, Mass.

Arch Gen Psychiatry. 1988;45(2):193-194.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The two articles on bupropion in this issue^1,2 remind us that this is one of several novel antidepressants that are generally assumed to be effective but are so far not available for the treatment of depressed patients. Bupropion is a particularly frustrating example of this group of drugs that seem always to be just out of reach. It was about to be released to the drug stores two years ago; it was suddenly called back and has not yet become available.

In an editorial a number of years ago, I noted that depression was a very satisfying disorder—good to study,

See also pp 139 and 145.

rewarding to treat, and almost always nicely treatable.³ Over the years, my optimism is wearing thin. One keeps suspecting that the "easy" cases of depression are now being treated by primary care physicians, leaving psychiatrists with a preponderance of depressed patients in . . . [Full Text PDF of this Article]

Footnotes
Accepted for publication Nov 16, 1987.

Reprint requests to Psychopharmacology Program, South Belkamp III, McLean Hospital, 115 Mill St, Belmont, MA 02178 (Dr Cole).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?